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Implication for health policy/practice/research/medical education:
in a study on 90 hypertensive and diabetic patients (45 hypertensive and 45 diabetic patients), we found, an inverse significant 
relationship between serum magnesium and triglyceride level in diabetic patients (P = 0.002, r = -0.458). Our study showed that 
serum magnesium may affect triglycerides levels in diabetic patients.
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Introduction: Both diabetes mellitus and hypertension are aspects of metabolic syndrome. 
Objectives: The aim of this study was to determine the relationship between serum magnesium 
level with resistant hyperlipidemia in a group of diabetic and hypertensive patients.
Patients and Methods:  The present cross-sectional study was carried out on 90 hypertensive and 
diabetic patients who referred to outpatient university clinic in Shahrekord (45 hypertensive and 45 
diabetic patients). Included patients had high triglyceride levels despite 8 weeks of treatment with 
lipid-lowering agents. 
Results: There was an inverse significant relationship between serum magnesium and triglyceride 
levels in diabetic patients (P = 0.002, r = -0.458), however, this correlation was not significant in 
hypertensive patients (P = 0.754, r = 0.048). 
Conclusion: This study showed, serum magnesium may affect triglycerides levels in diabetic 
patients, however, our finding requires further investigation with larger population.
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Diabetes mellitus, commonly, is known to be a metabolic 
disease characterized by high blood sugar levels over 
a long-period of time (1). There are many lipoprotein 
disorders in patients with uncontrolled diabetes. These 
metabolic disorders are due to the excessive production 
of triglyceride-rich lipoproteins of the liver, which is due 
to low levels of high-density lipoproteins (HDL). These 
patients also suffer from hypertriglyceridemia, which is 
due to a decrease in adipose tissue and lipoprotein lipase 
activity in the muscle tissues. Reduced HDL-C levels are 
due to plasma lipoprotein lipase (LPL) in catabolism of 
triglyceride-rich lipoproteins (2).
Hypertension is a chronic disease, in which arterial 
blood pressure rises. High blood pressure, can result in 
significant problems and increases the risk of cardiac and 
renal disease, stroke and also death (3,4).
Hyperlipidemia is common in patients with 
hypertension, but the causes of this condition are 
unknown. Additionally, treatment of hypertension with 
thiazide diuretics increases the risk of hyperlipidemia. 
 Magnesium (Mg) is the fourth most abundant cation 
in the body, as well as the second intracellular cation after 
potassium. For many enzymes involved in the metabolism 
of carbohydrates and lipids, Mg is an important cofactor 
(5). Hypomagnesemia is one of the most common 
electrolyte disorders in diabetic patients (6). Numerous 
studies have shown a relationship between magnesium 
deficiency with insulin resistance, diabetes, and 
hyperlipidemia (5). Additionally, epidemiological studies 
have shown an inverse relationship between magnesium 
intake and the level of blood pressure and the incidence 
of hypertension. It was also shown that hypertensive 
patients have lowered serum and intracellular magnesium 
than normal people (7). Mg plays an important role 
in lipoprotein lipase enzyme activity and removes 
triglyceride from blood. It is also essential for the activity 
of the enzyme, lecithin cholesterol acyltransferase 
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(LCAT), which converts free cholesterol into cholesterol 
esters and causes liver inflammation. Pyrophosphatase, an 
enzyme involved in lipid metabolism, also requires Mg for 
its activity. Therefore, in magnesium deficiency, enzymes 
are not properly efficient and accordingly dyslipidemia 
may happen (5). Recently it was shown that normal 
population with lower Mg levels, had lower HDL-C, 
higher triglyceride (TG), and also total cholesterol serum 
values (8).
Hyperlipidemia increases the incidence of cardiovascular 
events and subsequent mortalities in patients. Lipid 
abnormalities such as lowered serum HDL-C levels and 
increased triglyceride blood levels are common in type 
2 diabetes. Accordingly, lipid abnormalities in type 2 
diabetes and hypertensive patients, can be considered as a 
cause for development of atherosclerosis. The relationship 
between magnesium and cardiovascular risk factors has 
been proven in previous studies, however, there are many 
contradictory findings regarding the effect of magnesium 
on lipid profiles, as well as the control of blood sugar in 
diabetic patients. 
Objectives
Several studies have also proven the relationship between 
magnesium and hypertension, however few studies have 
been conducted on this subject. Serum magnesium is not 
commonly measured in diabetic and hypertensive patients, 
while recent investigation showed various metabolic 
complications have been attributed to hypomagnesemia. 
Hence this study was designed to detect the relationship 
between plasma magnesium levels and lipid profiles in 
diabetic and hypertensive individuals.
Patients and Methods 
Study design
The present cross-sectional study was carried out on 
90 hypertensive or diabetic patients who referred to 
outpatient university clinic in Shahrekord (45 hypertensive 
patients and 45 diabetic patients). Patients had high 
triglyceride levels despite eight weeks of treatment with 
lipid-lowering agents. Samples were gradually selected 
using convenience sampling method. Blood pressure was 
measured and recorded using an appropriate cuff under 
standard conditions. A total of 5 cc blood samples was 
taken from the patients after obtaining their consent letter, 
then blood cholesterol, triglyceride, HDL-C, low density 
lipoprotein (LDL-C), fasting blood glucose, and serum 
magnesium level were measured by standard methods. 
Ethical issues
Human rights were respected in accordance with the 
Helsinki Declaration 1975, as revised in 1983. The ethical 
committee of Shahrekord University of Medical Sciences 
(ethical code; IR.SKUMS.REC.1396.280) approved 
the study. The informed consents were taken from the 
patients. Besides, this study was extracted from the M.D, 
thesis of Pardis Kaveh at this University.
Statistical analysis
Collected, data entered in SPSS version 18 and analyzed 
using descriptive statistics, Pearson’s or Spearman 
correlation’s coefficient test, and also t test according 
to the distribution of data. Quantitative variables were 
investigated for normal distribution using Kolmogorov-
Smirnov test. All statistical differences were considered 
significant at the level of P value lower than 0.05.
Results
Out of 90 participants, 45 patients (50%) were included 
in group 1 (diabetic patients) and 45 (50%) in group 2 
(hypertensive patients). The mean ± SD of age, triglyceride, 
cholesterol, HDL-C, LDL-C, and serum magnesium of 
all participants was 60.41  ±  16.08 years, 216.76 ± 94.51 
mg/dL, 281.34 ± 38.31 mg/dL, 38.53 ± 11.15 mg/dL, 
201.04 ± 44.93 mg/dL and 1.97 ± 0.45 mg/dL, respectively. 
We found no statistically significant relationship between 
magnesium and cholesterol levels in total patients 
(P = 0.146, r=-0.155). Additionally, the relationship 
of magnesium with HDL-C (P = 0.228, r= -0.12), and 
LDL-C (P = 0.751, r= - 0.34) was also not significant in 
all cases. Spearman’s correlation analysis also showed no 
statistically significant relationship between magnesium 
level and fasting blood glucose in diabetic patients 
(P = 0.342, r = 0.145). Similarly, no significant relationship 
between serum magnesium with systolic and diastolic 
blood pressure in group 2 was detected (P = 0.893, r = 0.21 
and P = 0.347, r = -0.143 respectively). 
We also found, a significant correlation between serum 
magnesium and triglyceride level in group 1 (P = 0.002, 
r = -0.458; Spearman’s test, Figure 1), since in group 2 
this association was not significant (P = 0.75, r = 0.048). 
Figure 1. Significant correlation between serum magnesium and 
triglyceride level in diabetic patients (P = 0.002, r = -0.458; Spearman’s 
test).
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Likewise, no significant correlation between serum 
magnesium and cholesterol in group one (P = 0.11, 
r = -0.238) and group two (P = 0.59, r = -0.081) was detected. 
Accordingly, the association of serum magnesium with 
LDL-C in group one (P = 0.91, r = -0.16) and group two 
(P = 0.4, r = -0.12) was not significant. Besides HDL-C in 
group one (P = 0.64, r = - 0.071) and group two (P = 0.47, 
r = -0.1) were not associated with serum magnesium.
Discussion
The present study was carried out on 90 hypertensive and 
diabetic patients (45 hypertensive patients and 45 diabetic 
patients) with had high triglyceride levels despite a 
treatment period of 8 weeks with lipid-lowering drugs. In 
this study we found, plasma magnesium had relationship 
with serum triglyceride level in diabetic patients. However, 
the serum magnesium level does not correlate with fasting 
blood glucose, cholesterol, HDL-C, or LDL-C levels. 
Our results also showed that serum magnesium levels 
were not correlated with level of lipids or systolic and 
diastolic blood pressure in hypertensive patients. Diabetes 
mellitus is the most common disorder among endocrine 
disorders, which is associated with hypomagnesemia. 
Numerous studies have already shown that Mg levels are 
lower in diabetic patients (9-11). Reduced Mg level may 
cause insulin resistance (12, 13) and insufficient glucose 
control (14-16), and also dyslipidemia in diabetic patients 
(17). Previous studies have shown a significant negative 
correlation between Mg and fasting blood glucose (FBS) 
(9,11). However, our study didn’t show a significant 
correlation between Mg and FBS, which requires further 
larger studies. Marhalle et al (18) concluded that diabetes, 
dyslipidemia, and hypertension were inversely related to 
serum Mg, however we found no significant correlation 
between serum Mg with LDL-C, HDL-C, and triglyceride 
levels in hypertensive patients. We found, a significant 
correlation between serum Mg and triglyceride levels 
in diabetic patients. This finding is consistent with the 
result of a study by Arpaci et al (19). Various studies have 
suggested a direct relationship between Mg level and 
systolic blood pressure (20-22), however, results of the 
present study did not show this relationship while further 
studies are necessary for this reason. 
Conclusion
Results of the current study showed that magnesium 
(Mg) can affect triglycerides levels in diabetic patients 
suggesting an inverse relationship between serum 
magnesium and triglyceride levels. However, there is no 
relationship between the magnesium serum level with 
fasting blood glucose, cholesterol, HDL-C, or LDL-C 
levels. Moreover, there is no relationship between serum 
magnesium levels and the level of lipid profiles or to the 
level of systolic or diastolic hypertension in hypertensive 
patients. Considering the effect of serum magnesium 
level on reducing triglyceride levels in diabetic patients 
indicated in this study and the need for correction of lipid 
profiles in these patients, the administration of magnesium 
supplements in the treatment of diabetic patients may be 
necessary.
Limitation of the study
Our study conducted on a limited sample size of patients 
with resistant hyperlipidemia. This study needs further 
investigation on larger samples and also on all patients 
with hyperlipidemia without anti-lipid treatment.
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Table 1. Data of the patients
Group N Mean Std. Deviation Std. Error Mean
Age (years)
Diabetic 45 61.56 15.494 2.310
HTN 45 59.27 16.755 2.498
TG (mg/dL)
Diabetic 45 204.27 78.639 11.723
HTN 45 229.24 107.548 16.032
Cholesterol (mg/dL)
Diabetic 45 282.18 37.901 5.650
HTN 45 280.51  39.141 5.835
HDL-C (mg/dL) 
Diabetic 45 35.67 8.868 1.322
HTN 45 41.40 12.503 1.864
LDL-C (mg/dL)
Diabetic 45 206.69 45.206  6.739
HTN 45 195.40 44.451 6.626
Mg (mg/dL)
Diabetic 45 2.0916 0.47487 0.07079
HTN 45 1.8629 0.40823 0.06086
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